Huge breakthrough for oncology as scientists nail lung-cancer gene
Amgen’s lung-cancer treatment sotorasib has won approval from US regulators, becoming the first therapy to target a tumour-stoking genetic mutation scientists have tried to block for decades, reported Bloomberg (30 May 2021).
The drug is the first to directly target a mutant gene called KRAS G12C that is present in about 13 percent of non-small-cell lung cancers. Amgen’s therapy targets one of several KRAS mutations and is unlikely to be the last of its type approved. The treatment will cost $17 900 (about R250 000) a month, in line with other targeted lung-cancer therapies.